Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Agios Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Celgene
ClinicalTrials.gov Identifier:
NCT01915498
First received: July 31, 2013
Last updated: April 7, 2017
Last verified: April 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 31, 2018
  Estimated Primary Completion Date: December 31, 2017 (Final data collection date for primary outcome measure)